NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) granted stock options to purchase 151,250 shares of common stock to 12 recently hired employees, the company said following a November 24 action by its board’s Compensation Committee.
The awards were issued under the company’s 2025 New Hire Inducement Plan and structured as employment inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). Orchestra BioMed said 25% of each option award will vest on the employee’s one-year anniversary, with the remaining shares vesting quarterly over the following three years.
The company disclosed the awards to comply with exchange rules governing inducement equity grants.
Orchestra BioMed develops high-impact medical technologies through partnerships with major device manufacturers. Its two leading product candidates — Atrioventricular Interval Modulation (AVIM) Therapy and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) — are both in pivotal clinical trials and target multibillion-dollar global markets.
AVIM Therapy, a bioelectronic treatment for hypertension delivered as a pacemaker firmware upgrade, is being advanced through a strategic collaboration with Medtronic. The therapy holds FDA Breakthrough Device Designation and is aimed at millions of U.S. patients with uncontrolled hypertension despite medication.
Virtue SAB, also a Breakthrough Device–designated technology, is designed to deliver an extended-release formulation of sirolimus for coronary and peripheral artery disease, conditions that remain leading global causes of death.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.